|  |  |  |  |
| --- | --- | --- | --- |
| Receptor | Radioligand(concentration) | Receptor | Radioligand(concentration) |
| 5-HT1A | [3H]8-OH-DPAT (0.5 nM) | H3 | [3H]-alpha-methylhistamine (0.4 nM) |
| 5-HT1B | [3H]GR127543 (0.3 nM) | H4 | [3H]Histamine (5 nM) |
| 5-HT1D | [3H]GR127543 (0.3 nM) | SERT | [3H]Citalopram (0.5 nM) |
| 5-HT1E | [3H]5-HT (3 nM) | NET | [3H]Nisoxetine (0.5 nM) |
| 5-HT2A | [3H]Ketanserin (0.5 nM) | DAT | [3H]WIN35428 (0.5 nM) |
| 5-HT2B | [3H]LSD (1 nM) | BZP | [3H]Flunitrazepam (0.5 nM) |
| 5-HT2C | [3H]Mesulergine (0.5 nM) | Alpha1A | [3H]Prazosin (0.7 nM) |
| 5-HT3 | [3H]LY278584 (0.3 nM) | Alpha1B | [3H]Prazosin (0.7 nM) |
| 5-HT5a | [3H]LSD (1 nM) | Alpha2A | [3H]Clonidine (1 nM) |
| 5-HT6 | [3H]LSD (1 nM) | Alpha2B | [3H]Clonidine (1 nM) |
| 5-HT7 | [3H]LSD (1 nM) | Alpha2C | [3H]Clonidine (1 nM) |
| D1 | [3H]SCH233930 (0.2 nM) | Beta1 | [125I]Iodopindolol (0.1 nM) |
| D2 | [3H]N-methylspiperone (0.2 nM) | Beta2 | [125I]Iodopindolol (0.1 nM) |
| D3 | [3H]N-methylspiperone (0.2 nM) | Beta3 | [125I]Iodopindolol (0.1 nM) |
| D4 | [3H]N-methylspiperone (0.2 nM) | M1 | [3H]QNB (0.5 nM) |
| D5 | [3H]SCH233930 (0.2 nM) | M2 | [3H]QNB (0.5 nM) |
| DOR | [3H]DADLE (0.3 nM) | M3 | [3H]QNB (0.5 nM) |
| KOR | [3H]U69593 (0.3 nM) | M4 | [3H]QNB (0.5 nM) |
| MOR | [3H]DAMGO (0.3 nM) | M5 | [3H]QNB (0.5 nM) |
| H1 | [3H]Pyrilamine (0.9 nM) | Sigma-1 | [3H]Pentazocine (3 nM) |
| H2 | [3H]Tiotidine (3 nM) | Sigma-2 | [3H]DTG (3 nM) |
| PBR | [3H]PK11195 (1 nM) |  |  |

Additional experimental details available in NIMH PDSP protocol book. [1]